Minimal Residual Disease Testing Market Size & Share Analysis - Trends, Drivers, Competitive Landscape, and Forecasts (2024 - 2030)

Minimal Residual Disease Testing Market Size

Minimal Residual Disease Testing Market Trends & Drivers

Next-Generation Sequencing and Polymerase Chain Reaction Techniques Are Most-Frequently Used

• Next-generation sequencing and polymerase chain reaction are the most-commonly used techniques for minimal residual disease testing, as they provide faster and more-accurate results compared to others. Moreover, companies are focusing on the development of innovative and advanced assays that will utilize these techniques.
• For instance, in August 2022, Roche Diagnostics Corporation launched its digital LightCycler System, which is a next-generation digital PCR system. This system is capable of identifying and recognizing rather small quantities of specific DNA and RNA targets that are difficult to detect with standard PCR methods, thus leading to rapid diagnoses and treatment.

Minimal Residual Disease Testing Market Analysis

Hospitals To Witness Highest Growth Rate

The hospitals category is expected to grow at the highest rate, over 13% CAGR, in the market for minimal residual disease testing solutions during the forecast period, based on end user. This is due to the availability of cutting-edge diagnostic devices, along with highly skilled healthcare professionals at these places. The detection of the remaining cancerous cells plays an essential role in making well-informed long-term clinical decisions after the cancer therapy is completed. Hence, the efficacy of the diagnosis is crucial for healthcare insurance companies to provide financial support to cancer survivors worldwide.

Moreover, the COVID-19 pandemic has increased the health awareness among the population and its exposure to technology, which is why people are not taking any illness lightly. Moreover, to deal with the pandemic, countries around the world augmented their hospital network. For instance, in 2019, there were around 69,000 public and private hospitals all over India, and this number increased to 70,000 in 2020. Apart from COVID-19 diagnosis and isolation, these hospitals, in time, will provide services for acute as well as rare disorders, which will drive the growth of the hospitals category.

Hematological Malignancy To Witness Fastest Growth

The hematological malignancy category is expected to witness a CAGR of over 16% during the forecast timeline, due to the surging cases of leukemia around the world. According to the data published by the American Cancer Society, in 2022, approximately 8,540 new cases of Hodgkin’s lymphoma were diagnosed in the U.S., including 4,570 males and 3,970 females, along with 920 deaths. Additionally, survival rates have considerably increased in the past few years, mainly due to the advancements in the treatment, the efficacy of which depends on stage of the cancer.

Moreover, the rising R&D activities and the hike in the count of collaborations for product development are all responsible for the expansion of the market. For instance, in August 2020, Adaptive Biotechnologies Corporation received an expanded FDA approval for clonoSEQ Assay for assessing minimal residual diseases in patients with chronic lymphocytic leukemia, multiple myeloma, and acute lymphoblastic leukemia. This assay is a type of in-vitro diagnostic tool, which makes use of PCR and NGS to detect and monitor specific gene sequences in the DNA contained in the bone marrow of patients.

In addition, Adaptive Biotechnologies Corporation is collaborating with Laboratory Corporation of America and Phlebotek Solutions Corporation to offer more-suitable as well as safer options to withdraw blood from patients at home or at the laboratory.

Rising Adoption of Immunological Tests

The immunological test category held an around 30% share in 2022. This is primarily ascribed to the increasing awareness of the specific immunological tests that are designed to diagnose any illness in the body. The growing need for these tests is driven by the requirement to make predictions about cell proliferation and the reoccurrence of the disease, aided by the proficiency of advanced immunological tests in taking a quantitative measurement.

Recently, there have been major advancements in molecular diagnostic as well as monitoring techniques for individuals suffering from acute myeloid leukemia. Together with the continuous emergence of new therapeutic agents and immunological assays, these advanced diagnostic methods have led to a significant improvement in the treatment of various diseases.

Oncologists get insights into the effectiveness of the given therapy by conducting immunological tests for the monitoring of residual cancer cells during the course of treatment. It also helps them accurately predict the danger of a possible relapse of the illness, thus influencing their treatment choices, to yield improved therapeutic results.

Regional Analysis

North America Makes Largest Contribution to Global Revenue Generation

North America dominated the minimal residual disease testing market, with a revenue share of around 45%, in 2022, owing to the high research and development investments, rising adoption of technologically advanced solutions, presence of major players, and large number of testing facilities in the region.

The rising prevalence of the cancer of the blood-forming tissue in the U.S. has increased the chances of people possessing residual malignant cells, which would strengthen the need for minimal residual disease testing. According to the American Cancer Society, around 34,470 new cases of multiple myeloma and 6,660 new cases of acute lymphocytic leukemia were diagnosed in the U.S. in 2022.

Moreover, the rising demand for NGS and PCR for the detection of minimal residual diseases, rapid uptake of the latest instruments, and established proteomics, oncology, and genomics research infrastructure are propelling the market in the region.

The APAC market is expected to witness the fastest growth over the next few years. This growth can be attributed to the increasing prevalence of leukemia and lymphoma in the region, rising government spending on the healthcare infrastructure, availability of clinical laboratories, and easy access to novel diagnostic technologies in the region. In addition, the rapidly increasing number of hospitals in the APAC region is propelling the industry.

Japan is expected to hold the major share in the APAC region. This is due to the growing number of hospitals and diagnostics centers, together with the outstanding research base for diagnostic procedures. Additionally, the rising investment in the area of illness screening and the existence of supportive reimbursement policies are propelling the market growth.

Further, the region has a high prevalence of lymphoma, which creates a strong need for minimal residual disease testing. Furthermore, the key players are working on the development of novel minimal residual disease solutions, thus driving the growth of the market in the region.

Market Breakdown

This report offers deep insights into the minimal residual disease testing market, with size estimation for 2019 to 2030, the major drivers, restraints, trends and opportunities, and competitor analysis.

Based on Test Type

• DNA-Based Test
• RNA-Based Test
• Immunological Test

Based on Application

• Hematological Malignancies
  • Leukemia
  • Lymphoma
• Solid Tumors

Based on Technology

• Next-Generation Sequencing (NGS)
• Polymerase Chain Reaction (PCR)
• Flow Cytometry
• Fluorescence In-Situ Hybridization (FISH)

Based on End User         

• Hospitals
• Specialty Clinics
• Diagnostic Laboratories
• Research and Academic Institutes

Geographical Analysis

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
• Asia-Pacific
  • Japan
  • China
  • India
  • South Korea
  • Australia
• Latin America
  • Brazil
  • Mexico
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • U.A.E.

Top Minimal Residual Disease Testing Companies